Knockdown of endothelial NOS by lentivirus-mediated short hairpin RNA in hemangioendothelioma cells increases proliferation and tumor formation

Nitric Oxide - Biology and Chemistry

Volumn 16, Issue 4, 2007, Pages 403-412

  Chen, Zhi ^b   Joshi, Sarasijam ^a   Kauser, Katalin ^c   Brooks, Alan R ^a  

^a BAYER AG   (Germany)

^b BIOMARIN PHARMACEUTICAL INC   (United States)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Angiogenesis; ecNOS; Endothelium; Hemangioendothelioma; Knockdown; Nitric oxide; shRNA

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; MATRIGEL; MESSENGER RNA; NITRIC OXIDE; SHORT HAIRPIN RNA;

ANIMAL CELL; ARTICLE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENETIC CODE; GENETIC MANIPULATION; GENETIC TRANSFECTION; HEMANGIOENDOTHELIOMA; IN VITRO STUDY; IN VIVO STUDY; LENTIVIRINAE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; DOWN-REGULATION; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION; GENETIC VECTORS; HEMANGIOENDOTHELIOMA; LENTIVIRUS; MICE; NEOPLASM TRANSPLANTATION; NITRIC OXIDE SYNTHASE TYPE III; RNA, MESSENGER; RNA, SMALL INTERFERING;

LENTIVIRUS; MURINAE; MUS;

EID: 34249734792     PISSN: 10898603     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.niox.2007.03.001     Document Type: Article

References (37)

1. Loscalzo J., and Welch G. Nitric oxide and its role in the cardiovascular system. Prog. Cardiovasc. Dis. 38 (1995) 87-104
2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1 (1995) 27-31
3. Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S., and Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362 (1993) 841-844
4. Dimmeler S., Dernbach E., and Zeiher A.M. Phosphorylation of the endothelial nitric oxide synthase at ser-1177 is required for VEGF-induced endothelial cell migration. FEBS Lett. 477 (2000) 258-262
5. Lin M.I., and Sessa W.C. Vascular endothelial growth factor signaling to endothelial nitric oxide synthase: more than a FLeeTing moment. Circ. Res. 99 (2006) 666-668
6. Hoak J.C., Czervionke R.L., Fry G.L., Haycraft D.L., and Brotherton A.A. Role of the vascular endothelium. Philos. Trans. R Soc. Lond. B Biol. Sci. 294 (1981) 331-338
7. Obeso J., Weber J., and Auerbach R. A hemangioendothelioma-derived cell line: its use as a model for the study of endothelial cell biology. Lab. Invest. 63 (1990) 259-269
8. Felbor U., Dreier L., Bryant R.A., Ploegh H.L., Olsen B.R., and Mothes W. Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J. 19 (2000) 1187-1194
9. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., and Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88 (1997) 277-285
10. Lannutti B.J., Gately S.T., Quevedo M.E., Soff G.A., and Paller A.S. Human angiostatin inhibits murine hemangioendothelioma tumor growth in vivo. Cancer Res. 57 (1997) 5277-5280
11. O'Reilly M.S., Brem H., and Folkman J. Treatment of murine hemangioendotheliomas with the angiogenesis inhibitor AGM-1470. J. Pediatr. Surg. 30 (1995) 325-329 discussion 329-330
12. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., and Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411 (2001) 494-498
13. Abbas-Terki T., Blanco-Bose W., Deglon N., Pralong W., and Aebischer P. Lentiviral-mediated RNA interference. Hum. Gene. Ther. 13 (2002) 2197-2201
14. Paddison P.J., Caudy A.A., Bernstein E., Hannon G.J., and Conklin D.S. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev. 16 (2002) 948-958
15. Stewart S.A., Dykxhoorn D.M., Palliser D., Mizuno H., Yu E.Y., An D.S., Sabatini D.M., Chen I.S., Hahn W.C., Sharp P.A., Weinberg R.A., and Novina C.D. Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA 9 (2003) 493-501
16. Papapetropoulos A., Desai K.M., Rudic R.D., Mayer B., Zhang R., Ruiz-Torres M.P., Garcia-Cardena G., Madri J.A., and Sessa W.C. Nitric oxide synthase inhibitors attenuate transforming-growth-factor-beta 1-stimulated capillary organization in vitro. Am. J. Pathol. 150 (1997) 1835-1844
17. Fukumura D., Kashiwagi S., and Jain R.K. The role of nitric oxide in tumour progression. Nat. Rev. Cancer 6 (2006) 521-534
18. Jenkins D.C., Charles I.G., Thomsen L.L., Moss D.W., Holmes L.S., Baylis S.A., Rhodes P., Westmore K., Emson P.C., and Moncada S. Roles of nitric oxide in tumor growth. Proc. Natl. Acad. Sci. USA 92 (1995) 4392-4396
19. Kisley L.R., Barrett B.S., Bauer A.K., Dwyer-Nield L.D., Barthel B., Meyer A.M., Thompson D.C., and Malkinson A.M. Genetic ablation of inducible nitric oxide synthase decreases mouse lung tumorigenesis. Cancer Res. 62 (2002) 6850-6856
20. Ahn B., and Ohshima H. Suppression of intestinal polyposis in Apc(Min/+) mice by inhibiting nitric oxide production. Cancer Res. 61 (2001) 8357-8360
21. Ambs S., Merriam W.G., Ogunfusika M.O., Bennett W.P., Ishibe N., Hussain S.P., Tzeng E.E., Geller D.A., Billiar T.R., and Harris C.C. p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells. Nat. Med. 4 (1998) 1371-1376
22. Le X., Wei D., Huang S., Lancaster Jr. J.R., and Xie K. Nitric oxide synthase II suppresses the growth and metastasis of human cancer regardless of its up-regulation of protumor factors. Proc. Natl. Acad. Sci. USA 102 (2005) 8758-8763
23. Shi Q., Huang S., Jiang W., Kutach L.S., Ananthaswamy H.N., and Xie K. Direct correlation between nitric oxide synthase II inducibility and metastatic ability of UV-2237 murine fibrosarcoma cells carrying mutant p53. Cancer Res. 59 (1999) 2072-2075
24. Kashiwagi S., Izumi Y., Gohongi T., Demou Z.N., Xu L., Huang P.L., Buerk D.G., Munn L.L., Jain R.K., and Fukumura D. NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels. J. Clin. Invest. 115 (2005) 1816-1827
25. Qiu H., Orr F.W., Jensen D., Wang H.H., McIntosh A.R., Hasinoff B.B., Nance D.M., Pylypas S., Qi K., Song C., Muschel R.J., and Al-Mehdi A.B. Arrest of B16 melanoma cells in the mouse pulmonary microcirculation induces endothelial nitric oxide synthase-dependent nitric oxide release that is cytotoxic to the tumor cells. Am. J. Pathol. 162 (2003) 403-412
26. Ilan N., and Madri J.A. PECAM-1: old friend, new partners. Curr. Opin. Cell. Biol. 15 (2003) 515-524
27. Sheibani N., Newman P.J., and Frazier W.A. Thrombospondin-1, a natural inhibitor of angiogenesis, regulates platelet-endothelial cell adhesion molecule-1 expression and endothelial cell morphogenesis. Mol. Biol. Cell. 8 (1997) 1329-1341
28. Danen E.H., and Yamada K.M. Fibronectin, integrins, and growth control. J. Cell. Physiol. 189 (2001) 1-13
29. Boudreau N.J., and Jones P.L. Extracellular matrix and integrin signalling: the shape of things to come. Biochem. J. 339 Pt 3 (1999) 481-488
30. Friedlander M., Brooks P.C., Shaffer R.W., Kincaid C.M., Varner J.A., and Cheresh D.A. Definition of two angiogenic pathways by distinct alpha v integrins. Science 270 (1995) 1500-1502
31. Paik J.H., Chae S., Lee M.J., Thangada S., and Hla T. Sphingosine 1-phosphate-induced endothelial cell migration requires the expression of EDG-1 and EDG-3 receptors and Rho-dependent activation of alpha vbeta3- and beta1-containing integrins. J. Biol. Chem. 276 (2001) 11830-11837
32. Gerety S.S., Wang H.U., Chen Z.F., and Anderson D.J. Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development. Mol. Cell 4 (1999) 403-414
33. Pandey A., Shao H., Marks R.M., Polverini P.J., and Dixit V.M. Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF-alpha-induced angiogenesis. Science 268 (1995) 567-569
34. Fonsatti E., Altomonte M., Nicotra M.R., Natali P.G., and Maio M. Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels. Oncogene 22 (2003) 6557-6563
35. Duwel A., Eleno N., Jerkic M., Arevalo M., Bolanos J.P., Bernabeu C., and Lopez-Novoa J.M. Reduced tumor growth and angiogenesis in endoglin-haploinsufficient mice. Tumour Biol. 28 (2006) 1-8
36. Jerkic M., Rodriguez-Barbero A., Prieto M., Toporsian M., Pericacho M., Rivas-Elena J.V., Obreo J., Wang A., Perez-Barriocanal F., Arevalo M., Bernabeu C., Letarte M., and Lopez-Novoa J.M. Reduced angiogenic responses in adult endoglin heterozygous mice. Cardiovasc. Res. 69 (2006) 845-854
37. Larsson J., Goumans M.J., Sjostrand L.J., van Rooijen M.A., Ward D., Leveen P., Xu X., ten Dijke P., Mummery C.L., and Karlsson S. Abnormal angiogenesis but intact hematopoietic potential in TGF-beta type I receptor-deficient mice. EMBO J. 20 (2001) 1663-1673